Metacrine, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 32
- Market Cap
- -
- Website
- http://www.metacrine.com
Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Study to Evaluate MET642 in Patients With NASH
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Metacrine, Inc.
- Target Recruit Count
- 215
- Registration Number
- NCT04773964
- Locations
- 🇺🇸
Pinnacle Research, San Antonio, Texas, United States
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
Phase 2
- Conditions
- Fatty LiverType 2 DiabetesDiabetes Type 2DiabetesNAFLDNASHNASH - Nonalcoholic SteatohepatitisFatty Liver, Nonalcoholic
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Metacrine, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04702490
- Locations
- 🇺🇸
Metacrine Investigative Site, San Antonio, Texas, United States
News
No news found